Barriers and facilitators for family physicians prescribing opioid agonist therapy in Saskatchewan

被引:0
|
作者
Nguyen, Teresa [1 ]
Bareham, Julia [2 ]
Halpape, Katelyn [3 ]
机构
[1] Loblaw Pharm Saskatoon, Saskatoon, SK, Canada
[2] Univ Saskatchewan, RxFiles Acad Detailing Program, Saskatoon, SK, Canada
[3] Univ Saskatchewan, Coll Pharm & Nutr, Saskatoon, SK, Canada
关键词
COLLABORATIVE CARE; BUPRENORPHINE; EXPERIENCE; ABSTINENCE; ADDICTION; METHADONE;
D O I
10.46747/cfp.7004e52
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Objective To explore barriers and facilitators for family physicians in Saskatchewan prescribing opioid agonist therapy (OAT). Design Self-administered postal survey. Setting Family medicine practices in Saskatchewan. Participants A total of 218 Saskatchewan family physicians who were not authorized to prescribe OAT as of June 2022. Main outcome measures Descriptive and inferential statistics of physicians' self-reported barriers to and facilitators of prescribing OAT for opioid use disorder (OUD). Results Most respondents (84.8%) had some comfort with diagnosing OUD. However, more than half (58.3%) did not feel confident or knowledgeable about prescribing OAT. Barriers to OAT prescribing included lack of time, incomplete training requirements, lack of interest, insufficient funding or support, feeling overwhelmed, and perceiving that OAT does not work and thus is not necessary. Physicians working in core neighbourhoods and those receiving fee-for-service compensation reported the least available time to prescribe OAT. Conversely, physicians working in interdisciplinary team settings had increased time for OAT prescribing compared with physicians in other settings. Having a close personal relationship with someone with OUD was correlated with increased comfort in diagnosing OUD as well as with knowledge about and confidence in prescribing OAT. Themes identified as facilitators to increasing OAT prescribing included the addition of resources and supports, increased training, more awareness about OUD and OAT, enhanced compensation, and altered prescribing regulations. Conclusion Despite the presence of several real and perceived barriers limiting OAT prescribing by Saskatchewan family physicians, there are family physicians interested in providing this therapy. Increased clinical resources and support, including increased interdisciplinary practice, are actionable steps that should be considered by policy decision makers to address this issue. Additionally, increased OUD and OAT education, which includes the perspectives of those with lived experience of OUD, would help address physician confidence, knowledge, and awareness in this area.
引用
收藏
页码:e52 / e60
页数:9
相关论文
共 50 条
  • [41] Barriers to Post-Acute Care for Patients on Opioid Agonist Therapy; An Example of Systematic Stigmatization of Addiction
    Sarah E. Wakeman
    Josiah D. Rich
    Journal of General Internal Medicine, 2017, 32 : 17 - 19
  • [42] Comparing Canadian and United States opioid agonist therapy policies
    Priest, Kelsey C.
    Gorfinkel, Lauren
    Klimas, Jan
    Jones, Andrea A.
    Fairbairn, Nadia
    McCarty, Dennis
    INTERNATIONAL JOURNAL OF DRUG POLICY, 2019, 74 : 257 - 265
  • [43] Legal and policy changes urgently needed to increase access to opioid agonist therapy in the United States
    Davis, Corey S.
    Carr, Derek H.
    INTERNATIONAL JOURNAL OF DRUG POLICY, 2019, 73 : 42 - 48
  • [44] Evaluating the Impact of Increased Dispensing of Opioid Agonist Therapy Take-Home Doses on Treatment Retention and Opioid-Related Harm among Opioid Agonist Therapy Recipients: A Simulation Study
    Shojaati, Narjes
    Osgood, Nathaniel D.
    SYSTEMS, 2023, 11 (08):
  • [45] Prescribing Buprenorphine for Opioid Use Disorders in the ED: A Review of Best Practices, Barriers, and Future Directions
    Cao, Scott S.
    Dunham, Samuel, I
    Simpson, Scott A.
    OPEN ACCESS EMERGENCY MEDICINE, 2020, 12 : 261 - 274
  • [46] Chronic pain, craving, and illicit opioid use among patients receiving opioid agonist therapy
    Tsui, Judith I.
    Lira, Marlene C.
    Cheng, Debbie M.
    Winter, Michael R.
    Alford, Daniel P.
    Liebschutz, Jane M.
    Edwards, Robert R.
    Samet, Jeffrey H.
    DRUG AND ALCOHOL DEPENDENCE, 2016, 166 : 26 - 31
  • [47] Quality Hospice Care in Adult Family Homes: Barriers and Facilitators
    Washington, Karla T.
    Demiris, George
    Oliver, Debra Parker
    Purnell, Gemille
    Tatum, Paul
    JOURNAL OF THE AMERICAN MEDICAL DIRECTORS ASSOCIATION, 2018, 19 (02) : 136 - 140
  • [48] How Family Physicians Can Combat the Opioid Epidemic
    Middleton, Jennifer L.
    AMERICAN FAMILY PHYSICIAN, 2017, 96 (06) : 357 - 358
  • [49] Barriers to Buprenorphine Prescribing for Opioid Use Disorder in Hospice and Palliative Care
    Ho, Jiunling Janet
    Jones, Katie Fitzgerald
    Sager, Zachary
    Neale, Kyle
    Childers, Julie W.
    Loggers, Elizabeth
    Merlin, Jessica S.
    JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 2022, 64 (02) : 119 - 127
  • [50] The Affordable Care Act and Opioid Agonist Therapy for Opioid Use Disorder
    Mojtabai, Ramin
    Mauro, Christine
    Wall, Melanie M.
    Barry, Colleen L.
    Olfson, Mark
    PSYCHIATRIC SERVICES, 2019, 70 (07) : 617 - 620